RedHill Biopharma (RDHL) Total Non-Current Liabilities (2014 - 2025)
RedHill Biopharma (RDHL) posted quarterly Total Non-Current Liabilities of $1.9 million for Q4 2025, up 268.99% year-over-year from $503000.0 in Q4 2024, and up 271.2% quarter-over-quarter from $500000.0 in Q2 2025.
RedHill Biopharma (RDHL) Total Non-Current Liabilities (2014 - 2025) Analysis & Trends
RedHill Biopharma (RDHL) has reported Total Non-Current Liabilities for 11 consecutive years, with $1.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 268.99% year-over-year to $1.9 million; the TTM figure through Dec 2025 stood at $1.9 million (up 268.99% YoY), while the FY2025 annual figure was $1.9 million, up 268.99% from the prior year.
- Total Non-Current Liabilities grew to $1.9 million in Q4 2025 per RDHL's latest filing, from $500000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $94.9 million in Q2 2021 and bottomed at $500000.0 in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $21.7 million across 5 years, with a median of $2.6 million in 2023.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities tumbled 89.86% — and 2025, when it soared 268.99%.
- RedHill Biopharma's Total Non-Current Liabilities stood at $90.8 million in 2021, then sank by 89.19% to $9.8 million in 2022, then sank by 89.86% to $995000.0 in 2023, then sank by 49.45% to $503000.0 in 2024, then jumped by 268.99% to $1.9 million in 2025.
- Business Quant data shows RDHL's Total Non-Current Liabilities at $1.9 million in Q4 2025, $500000.0 in Q2 2025, and $503000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 334.00 Mn |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.86 Mn |
| Jun 30, 2025 | 500,000.00 |
| Dec 31, 2024 | 503,000.00 |
| Jun 30, 2024 | 730,000.00 |
| Dec 31, 2023 | 995,000.00 |
| Jun 30, 2023 | 3.38 Mn |
| Dec 31, 2022 | 9.82 Mn |
| Jun 30, 2022 | 13.49 Mn |
| Dec 31, 2021 | 90.84 Mn |
| Jun 30, 2021 | 94.92 Mn |
| Dec 31, 2020 | 93.14 Mn |
| Jun 30, 2020 | 95.91 Mn |
| Dec 31, 2019 | 3.48 Mn |
| Jun 30, 2019 | 3.74 Mn |
| Dec 31, 2018 | 844,000.00 |
| Dec 31, 2017 | 448,000.00 |
| Dec 31, 2015 | 1.24 Mn |
| Dec 31, 2014 | 2.13 Mn |